Champions Oncology
CSBR
23 hedge funds and large institutions have $31.5M invested in Champions Oncology in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 5 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.21% less ownership
Funds ownership: 42.57% → 41.36% (-1.2%)
12% less capital invested
Capital invested by funds: $35.6M → $31.5M (-$4.1M)
21% less funds holding
Funds holding: 29 → 23 (-6)
51% less call options, than puts
Call options by funds: $69K | Put options by funds: $141K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
Tocqueville Asset Management
New York
|
+$107K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$79K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$77.5K |
| 4 |
Morgan Stanley
New York
|
+$39.6K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$20.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OMC
Overbrook Management Corp
New York
|
-$301K |
| 2 |
Millennium Management
New York
|
-$208K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$180K |
| 4 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$157K |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
-$64.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Stifel Financial
St. Louis,
Missouri
| – | -$64.8K | -10,442 | Closed |
|
27
Simplex Trading
Chicago,
Illinois
| – | -$6K | -1,064 | Closed |
|
|
TRCT
28
Tower Research Capital (TRC)
New York
| – | -$130 | -21 | Closed |
|
CSBR Hedge Fund Activity: Q4 2023 in Review
23 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Champions Oncology (CSBR) for Q4 2023, worth a combined $31.5M — down 12% from $35.6M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CSBR and 0 opened new positions — a net loss of 5 holders — while 7 trimmed existing stakes and 8 added.
The largest buyer was Tocqueville Asset Management, adding an estimated $107K. The largest seller was Overbrook Management Corp, exiting entirely with an estimated $301K sold.
- 23 institutional investors held Champions Oncology (CSBR) as of Q4 2023, down from 29 in Q3 2023.
- Funds reported $31.5M of Champions Oncology stock for Q4 2023, down 12% quarter-over-quarter.
- 0 funds opened new Champions Oncology positions in Q4 2023 and 5 closed out, a net change of -5 holders.
- The largest Champions Oncology buyer in Q4 2023 was Tocqueville Asset Management, an estimated $107K added.
- The largest Champions Oncology seller in Q4 2023 was Overbrook Management Corp, an estimated $301K sold.
Based on aggregated 13F filings for Q4 2023.